After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro ...
Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced ...
CMO Dietmar Berger leads Gilead's R&D efforts with 54 clinical programs, anticipating Sunlenca's HIV PrEP launch & touting no ...
Chinese API manufacturers Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical have been placed on US import alert ...
SpringWorks Therapeutics, a biotech potentially on the verge of being acquired, won its second FDA approval. Get ...
Biohaven lands priority review on second-chance application for neurodegenerative drug
FDA grants priority review for Biohaven's troriluzole for spinocerebellar ataxia after real-world data submission. Decision ...
Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known ...
Health acquires Caraway Health, merging pediatric urgent care with Gen Z virtual care. The deal is another tying together two ...
A federal court in Massachusetts temporarily blocked the Trump administration’s new cap on indirect cost reimbursements for ...
Major pharma firms like Eli Lilly, GSK, Merck, Regeneron and Sanofi announce $35B+ in share buybacks since December, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results